December 15, 2004
TAP SUBMITS NEW DRUG APPLICATION FOR FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN CHRONIC GOUT

October 19, 2004
DATA PRESENTED AT AMERICAN COLLEGE OF RHEUMATOLOGY MEETING ON FEBUXOSTAT, AN INVESTIGATIONAL THERAPY FOR HYPERURICEMIA ASSOCIATED WITH GOUT

October 19, 2004
PHASE III INVESTIGATIONAL MEDICATION, FEBUXOSTAT, BEING STUDIED FOR LOWERING URIC ACID LEVELS IN GOUT PATIENTS

October 1, 2004
TAP ANNOUNCES NEW EXECUTIVE VICE PRESIDENT

August 31, 2004
TAP ANNOUNCES NEW PRESIDENT

July 6, 2004
FDA APPROVES NEW DOSING OPTIONS FOR PREVACID® (LANSOPRAZOLE) SOLUTAB™ ORALLY DISINTEGRATING TABLETS

June 30, 2004
PREVACID® (LANSOPRAZOLE) APPROVED BY FDA FOR USE IN ADOLESCENTS

June 1, 2004
PREVACID® I.V. (LANSOPRAZOLE) FOR INJECTION APPROVED BY THE FDA FOR THE TREATMENT OF EROSIVE ESOPHAGITIS IN HOSPITALIZED PATIENTS

April 8, 2004
TAP PHARMACEUTICAL PRODUCTS INC. RECOGNIZED FOR INNOVATIVE EMPLOYEE HEALTH PROGRAM

March 5, 2004
TAP PHARMACEUTICAL PRODUCTS INC. NAMES BRIAN LUEDTKE TO HEAD PREVACID MARKETING EFFORTS

January 30, 2004
FOOTBALL LEGEND JOHN ELWAY LAUNCHES THE ROAD TO RELIEF, A NATIONAL CAMPAIGN TO EDUCATE ABOUT THE POTENTIAL SERIOUSNESS OF PERSISTENT HEARTBURN AND MOTIVATE SUFFERERS TO TALK TO THEIR DOCTOR